© Drug Hunter Inc. 2018-2023
Home > AG-636
dihydroorotate dehydrogenase inhibitor
in Ph. I for RR-lymphoma
from opt. of literature molecule
Mol. Cancer Ther., Oct. 20, 2020
Agios Pharmaceuticals, Cambridge, MA
AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year